First-in-Human study of LMB763, a novel, orally-available farnesoid X receptor agonist that demonstrates modulation of the pharmacodynamic markers FGF19 and C4 in healthy subjects

Saved in:
Bibliographic Details
Published inJournal of hepatology Vol. 66; no. 1; p. S425
Main Authors Huttner, K, Desai, S, DeCristofaro, M, Laffitte, B, Lin, T, Chen, J, Klickstein, L, Badman, M.K
Format Journal Article
LanguageEnglish
Published 2017
Subjects
Gastroenterology and Hepatology
Online AccessGet full text

Cover

More Information
ISSN:0168-8278
DOI:10.1016/S0168-8278(17)31214-X